Metformin for People With Idiopathic Pulmonary Fibrosis at High Risk of Worsening

Trial details

Who runs it

University of Massachusetts, Worcester

Trial code

NCT07520110

Record updated

8 September 2026

Original description

This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in participants with IPF who are at high-risk for adverse clinical events.Read full original descriptionShow less

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC)

This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in participants with IPF who are at high-risk for adverse clinical events.

Approximately 800 participants with IPF will be screened. 400 participants who are at high risk for adverse clinical events (proteomic signature present) will be randomized into receiving metformin (n~200) or matching placebo (n~200). Participants that meet the eligibility criteria but do not have the proteomic signature (proteomic signature absent) will be contacted by phone at 12 and 24 months to review medical history.

Inclusion: IPF diagnosis by enrolling investigator (following the 2022 updated guidelines on diagnosis and management of IPF); Age 40 years or older; HbA1c < 9% at screening; High risk by proteomic signature (proteomic signature present) for participants randomized only (for participants randomized only; participants that are proteomic signature absent will undergo remote study assessments at 12 and 24 months only); If on FDA-approved treatment(s) for IPF, on a stable dose for at least 8 weeks prior to randomization; Ability to provide informed consent.

Exclusion: Taking a medication that has a major interaction with metformin, including acetazolamide (Diamox), cimetidine (Tagamet), dolutegravir, gatifloxacin, levoketoconazole, ranolazine, or carbonic anhydrase inhibitors. Occasional use of carbonic anhydrase inhibitors for travel is permitted; Listed for transplant at the time of randomization; Allergy or intolerance to metformin; Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year during study participation; Moderate-to-severe liver disease, decompensated heart failure, or any other condition that may make the participant unsuitable for inclusion as assessed by the study investigator at each site; History of biochemically-confirmed acidosis (lactate > 5.0 mmol/L); Taking metformin within 3 months of randomization; Use of insulin or insulin secretagogue(s) at randomization; Pregnancy, planning to become pregnant, or lactating; Estimated glomerular filtration rate less than 45 mL/min/1.73 m2 at screening; Receipt of an investigational study agent as part of a therapeutic trial within 30 days of the Screening Visit (Visit 0); Continuous supplemental oxygen use at rest greater than 2 L/min; Unable to swallow pills; Current alcohol intake ≥ 15 drinks per week in men, ≥ 8 drinks per week in women or ≥ 5 drinks per occasion in men, ≥ 4 drinks per occasion in women.

ClinicalTrials.gov NCT07520110